Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

749.92 -3.49 (-0.46%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
One key disease-prevention market is drawing closer to being within reach. 
Via The Motley Fool
Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock
The odds of its new drug getting established in the U.K. are now much lower. 
Via The Motley Fool
Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
Elon Musk hinted that Neuralink may develop a brain implant to treat early-stage Alzheimer's, although he noted its limited effectiveness for advanced cases due to extensive neuronal loss. 
Via Benzinga
Eli Lilly's Mirikizumab Shows Long-Term Sustained Efficacy, Safety For Ulcerative Colitis And Crohn's Disease
Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative colitis and Crohn's disease patients. 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.
Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter. 
Via The Motley Fool
2 Soaring Growth Stocks That Are Still Worth Buying
These two companies -- leaders in their industries -- look unstoppable. 
Via The Motley Fool
Tesla To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks. 
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Gary Black Fights Off Criticism, Says Worst Peformer In Future Fund Was Tesla — Here Are His Holdings That Did Better
Gary Black, Managing Partner of The Future Fund LLC, shared insights on social media platform X regarding his investment performance since January 2022. 
Via Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss. 
Via Investor's Business Daily
Exposures Product Safety
Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: 'Wait For A Pullback'
On CNBC's "Mad Money Lightning Round," Jim Cramer said no to Nextracker. "Nextracker's a mistake that I made," he added. 
Via Benzinga
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
Eli Lilly Alzheimer's Drug Faces Tough Road In UK, Price Watchdog NICE Says Donanemab Is Not Cost-Effective
Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease. 
Via Benzinga
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
These three Vanguard ETFs are worth considering for the long term. 
Via The Motley Fool
Topics ETFs
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Fewer contenders means fewer constraints on expanding market share. 
Via The Motley Fool
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering counterfeit versions of Zepbound and Mounjaro 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Eli Lilly just secured a huge win, and it's not related to the weight loss industry. 
Via The Motley Fool
Investing $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million
These hot growth stocks may not be running out of steam just yet. 
Via The Motley Fool
AskSlim Market Week - Friday, Oct. 19
An analysis and commentary on the financial markets. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.